Skip to main content
. 2021 Sep 24;12:759267. doi: 10.3389/fphar.2021.759267

FIGURE 3.

FIGURE 3

Inhibition of LINC01001 depresses crizotinib-resistance of NSCLC in vivo. (A) Tumor size. (B) Statistical analysis of tumor volume (3 days). (C) Statistical analysis of tumor weight (15 days). (D) H&E staining and IHC staining assessed the level of Ki67 in tumor tissues (15 days). **p < 0.01, ***p < 0.001 vs sh-NC group. Error bars represent SD. Data represent three independent experiments.